Mod GRF 1-29

Growth Hormone Secretagogues

aka CJC-1295 without DAC · (D-Ala2,Gln8,Ala15,Leu27)-GRF amide · Modified GRF 1-29

Compare

Formula

MW (Da)

Half-life

~30 min

Saves

Overview

Mod GRF 1-29 is commonly treated as the same molecule as CJC-1295 without DAC — a short-acting, stabilized analog of the active N-terminal portion of GHRH. Peer-reviewed analytical literature identifies the molecule as (D-Ala2, Gln8, Ala15, Leu27)-GRF amide, distinguishing it from longer-acting DAC-containing forms.

Mechanism

The intended mechanism is straightforward: agonism of the GHRH receptor on pituitary somatotrophs to increase pulsatile GH release. The four substitutions are designed for improved potency and stability versus native GRF(1-29), whose half-life is very short. Older human and animal work on D-Ala2 and related GHRH analogs found stronger GH-releasing activity and modest half-life extension compared with native GRF(1-29). Mod GRF 1-29 is a receptor agonist in the GH axis — not a downstream growth factor like MGF, and not a ghrelin mimetic.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Stronger GH release and modest half-life extension vs native GRF(1-29)

Older human and animal work on D-Ala2 and related GHRH analogs found stronger GH-releasing activity and modest half-life extension compared with native GRF(1-29).

[modgrf-pubmed-grfana]

clinical

Clean receptor logic on the GH axis

Mod GRF 1-29 is a GHRH receptor agonist, not a downstream growth factor or ghrelin mimetic — the pharmacology is mechanistically straightforward even where the product-quality story is not.

[modgrf-pubchem]

preclinical

Reported side effects

FDA: characterization, aggregation, immunogenicity, impurity concerns
clinical
FDA briefing documents note concerns about poor characterization, peptide aggregation, immunogenicity, impurities, and endotoxin control for CJC-1295 forms, including injection products.
No FDA-approved dosing standard
clinical
There is no FDA-approved dosing standard for Mod GRF 1-29 or CJC-1295 without DAC. Older diagnostic or investigational GRF dosing studies should not be treated as interchangeable with current compounded products.

Dosing notes

There is no FDA-approved dosing standard for Mod GRF 1-29 or CJC-1295 without DAC. Older diagnostic or investigational GRF dosing studies should not be treated as interchangeable with current compounded products.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

No approved finished-drug label exists, so no validated storage instructions are available. Standard synthetic-peptide handling: dry frozen storage, typically -20°C or below, then aliquoting and cold storage after reconstitution.

Vendors carrying Mod GRF 1-29

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about Mod GRF 1-29.

No questions yet. Be the first to ask.

References

[modgrf-pubchem]
CJC-1295 without DAC (PubChem) — (D-Ala2,Gln8,Ala15,Leu27)-GRF amide
PubChem · PubChem
Source
[modgrf-pubmed-grfana]
D-Ala2 GRF and related GHRH analogs: GH-release and stability
Authors per PubMed entry · PubMed
Source
[modgrf-fda-bulk]
FDA: certain bulk drug substances for use in compounding may present significant safety risks
U.S. FDA · FDA
Source